Akash Tewari
Stock Analyst at Jefferies
(2.44)
# 2,429
Out of 5,133 analysts
61
Total ratings
39.13%
Success rate
4.68%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Buy | $28 → $35 | $34.45 | +1.60% | 2 | Nov 3, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $83 → $96 | $79.48 | +20.79% | 2 | Sep 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $813 → $831 | $758.91 | +9.50% | 5 | Aug 27, 2025 | |
| CBIO Crescent Biopharma | Initiates: Buy | $26 | $11.05 | +135.29% | 1 | Aug 25, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $12.29 | -18.63% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $55.92 | +21.60% | 4 | Apr 23, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $55.20 | +72.10% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $107.19 | +39.94% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $7.94 | +101.51% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $132.26 | +42.90% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $21.33 | +275.06% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $994 → $1,015 | $1,077.19 | -5.77% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $29.15 | +71.53% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $79.00 | -5.06% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $31.53 | -1.68% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $25.15 | +55.07% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $13.13 | +37.09% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $810.51 | -36.71% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $108.26 | +15.46% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $23.92 | -54.01% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.70 | +900.00% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $63.33 | +18.43% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $493.90 | -69.43% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $44.08 | -36.48% | 3 | Oct 7, 2021 |
Terns Pharmaceuticals
Nov 3, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $34.45
Upside: +1.60%
Ionis Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $83 → $96
Current: $79.48
Upside: +20.79%
Regeneron Pharmaceuticals
Aug 27, 2025
Maintains: Buy
Price Target: $813 → $831
Current: $758.91
Upside: +9.50%
Crescent Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $26
Current: $11.05
Upside: +135.29%
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $12.29
Upside: -18.63%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $55.92
Upside: +21.60%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $55.20
Upside: +72.10%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $107.19
Upside: +39.94%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $7.94
Upside: +101.51%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $132.26
Upside: +42.90%
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $21.33
Upside: +275.06%
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $1,077.19
Upside: -5.77%
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $29.15
Upside: +71.53%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $79.00
Upside: -5.06%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $31.53
Upside: -1.68%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $25.15
Upside: +55.07%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $13.13
Upside: +37.09%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $810.51
Upside: -36.71%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $108.26
Upside: +15.46%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $23.92
Upside: -54.01%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.70
Upside: +900.00%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $63.33
Upside: +18.43%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $493.90
Upside: -69.43%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $44.08
Upside: -36.48%